{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:04:19Z","timestamp":1778893459779,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014204","name":"Gateway Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA098258"],"award-info":[{"award-number":["CA098258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA217685"],"award-info":[{"award-number":["CA217685"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA217842"],"award-info":[{"award-number":["CA217842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016943","name":"Prospect Creek Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001282","name":"Ovarian Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT22-17"],"award-info":[{"award-number":["SU2C-AACR-DT22-17"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA197588"],"award-info":[{"award-number":["R35CA197588"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009845","name":"Ovarian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006535","name":"Entertainment Industry Foundation","doi-asserted-by":"publisher","award":["SU2C-AACR-DT0209"],"award-info":[{"award-number":["SU2C-AACR-DT0209"]}],"id":[{"id":"10.13039\/100006535","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.gore.2020.100546","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T11:56:18Z","timestamp":1580730978000},"page":"100546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-7853","authenticated-orcid":false,"given":"Elizabeth K.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenying","family":"Tan-Wasielewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis C.","family":"Cantley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Austin","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2020.100546_b0005","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.gore.2020.100546_b0010","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.gore.2020.100546_b0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","article-title":"Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms","volume":"5","author":"Nakayama","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.gore.2020.100546_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055362","article-title":"Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma","volume":"8","author":"De Marco","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gore.2020.100546_b0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2009.06.006","article-title":"Evidence that inositol polyphosphate 4-phosphatase type II Is a tumor suppressor that inhibits PI3K signaling","volume":"16","author":"Gewinner","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1016\/j.gore.2020.100546_b0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I Phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2020.100546_b0035","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.gore.2020.100546_b0040","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Yap","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2020.100546_b0045","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/jco.2009.27.15_suppl.3503","article-title":"A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST)","volume":"27","author":"Tolcher","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2020.100546_b0050","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12094-018-1888-2","article-title":"Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial","volume":"20","author":"Kalinsky","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.gore.2020.100546_b0055","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1158\/1078-0432.CCR-14-0868","article-title":"Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers","volume":"20","author":"Yap","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2020.100546_b0060","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdw676","article-title":"A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma","volume":"28","author":"Jonasch","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.gore.2020.100546_b0065","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.29363","article-title":"Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005)","volume":"121","author":"Ramanathan","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.gore.2020.100546_b0070","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1158\/1078-0432.CCR-17-1260","article-title":"A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA -mutant ER-positive and HER2-negative breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2020.100546_b0075","first-page":"12122","article-title":"Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced","volume":"5","author":"Ahn","year":"2015","journal-title":"Biliary Cancer., Sci. Rep."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:56:26Z","timestamp":1762480586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578920300126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":15,"alternative-id":["S2352578920300126"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2020.100546","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2020.100546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100546"}}